March 19, 2024 01:47 PM EDT
Manufacturing

No­var­tis’ CD­MO arm eyes growth, scope to wel­come com­peti­tors’ clients 

Anna Brown

News Reporter

As No­var­tis ex­pands its CD­MO busi­ness, it says it is al­so “in dis­cus­sions” to fur­ther boost its client list amid cur­rent “dis­rup­tive mo­ments” in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times